BI-7273|1883429-21-7|-陌孚医药/Medlife

您当前的位置：

BI-7273

目录号: PL13477 纯度: ≥99%

CAS No. :1883429-21-7

Medlife所售产品仅用于科学研究（非临床研究），非药品不可食用，不可用于人体或动物的临床诊断和治疗，我们不为个人提供产品及服务。产品COA等资料，可至下方“质量控制”中下载。

加入购物车在线咨询收藏产品大包装询价

中文名称	BI-7273
中文别名	BRD9BD抑制剂(BI-7273);化合物BI7273
英文名称	BI-7273
英文别名	BI-7273;BI7273;4-[4-[(Dimethylamino)methyl]-3,5-Dimethoxy-Phenyl]-2-Methyl-2,7-Naphthyridin-1-One;4-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-2-methyl-2,7-naphthyridin-1-one;4-{4-[(dimethylamino)methyl]-2,6-dimethoxyphenyl}-2-methyl-1,2-dihydro-2,7-naphthyridin-1-one;4-(4-((Dimethylamino)methyl)-3,5-dimethoxyphenyl)-2-methyl-2,7-naphthyridin-1(2H)-one;4-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-2-methyl-2,7-naphthyridin-1(2H)-one;5SW;GTPL9146;BI273;BI 7273;CS-2327;2,7-Naphthyridin-1(2H)-one, 4-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-2-methyl-;inhibit,Inhibitor,Epigenetic Reader Domain,BI7273,BI-7273,BI 7273;4-(4-((dimethylamino)methyl)-2,6-dimethoxyphenyl)-2-methyl-2,7-naphthyridin-1(2H)-one
Cas No.	1883429-21-7
分子式	C₂₀H₂₃N₃O₃
分子量	353.41
包装储存	Powder -20°C 3 years；4°C 2 years

产品详情	BI-7273 是一种选择性的，细胞透过的 BRD9 抑制剂，IC₅₀ 和 K_d 分别为 19 和 0.75 nM；同时对 BRD7 的作用较强，IC₅₀ 和 K_d 值分别为 117 nM 和 0.3 nM。
生物活性	BI-7273 is a selective, and cell-permeable BRD9 inhibitor, with an IC 50 and a K d of 19 and 0.75 nM; also shows high effect on BRD7, with an IC 50 and a K d of 117 nM and 0.3 nM.
性状	Solid
IC50 & Target[1][2]	IC50: 19 nM (BRD9), 117 nM (BRD7) Kd: 0.75 nM (BRD9), 0.3 nM (BRD7)
体外研究(In Vitro)	BI-7273 is a selective, and cell-permeable BRD9 inhibitor, with an IC50 and a Kd of 19 and 0.75 nM; also shows high effect on BRD7, with an IC50 and a Kd of 117 nM and 0.3 nM. BI-7273 also has slight activity against a panel of kinases such as CECR2, BRPF1, BRD1, CREBBP, EP300, FALZ, TAF1(2) and TAF1L(2), with Kds of 8.8 nM, 210 nM, 2600 nM, 8600 nM, 10000 nM, 850 nM, 1000 nM, and 1200 nM, respectively. BI-7273 (1 μM) is active in U2OS cell lines. BI-7273 blocks EOL-1 cell proliferation with EC50 of 1400 nM. has not independently confirmed the accuracy of these methods. They are for reference only.
运输条件	Room temperature in continental US; may vary elsewhere.
储存方式	Powder -20°C 3 years；4°C 2 years
参考文献	[1]. Martin LJ, et al. Structure-Based Design of an in Vivo Active Selective BRD9 Inhibitor. J Med Chem. 2016 May 26;59(10):4462-75.

溶解度数据	In Vitro: DMSO : 10 mg/mL (28.30 mM; Need ultrasonic)配制储备液

搜索质检报告(COA)

1：一般建议：溶解度为Medlife测试数据，可能与文献描述存在差异。这是由于生产工艺和批次不同产生的正常现象。为了使其更好的溶解，请用37℃加热试管并在超声波水浴中震动片刻。不同批次产品溶解度各有差异，仅做参考，具体以实验方案为准。

2：储存条件：粉末-20°C一般情况可以保存3年，溶于溶剂-80°C一般情况可以保存1年。不同产品及不同批次产品可能存在差异，请细致阅读产品信息，并辅助参考相关文献描述。

相关产品